Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sICASBLM: PCSK9 Inhibitors in Symptomatic Intracranial Atherosclerotic Stenosis
NCT05397405Recruiting
- Sponsor
- Nanjing First Hospital
- Start
- May 2022
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Trial in Intracranial atherosclerotic stenosis (ICAS) (2 arms), sponsored by Nanjing First Hospital. Primary endpoint: Recurrent stroke at 12 months. Started May 2022; status: recruiting.
02
Conditions
Intracranial atherosclerotic stenosis (ICAS)
Beyond the preview
Go deeper on NCT05397405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05397405.